{
    "clinical_study": {
        "@rank": "43736", 
        "acronym": "LIGHT-ON", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Active Comparator", 
                "description": "Liraglutide combined with metformin"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Insulin glargine combined with metformin"
            }, 
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "Sitagliptin combined with metformin"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to explore the effectiveness of liraglutide combined with metformin\n      in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared\n      to sitagliptin and insulin glargine in combination with metformin."
        }, 
        "brief_title": "Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-alcoholic Fatty Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a 26-week, randomized, open-label, active controlled, parallel group, multi-centre\n      trial.To compare the change of intrahepatic lipids (IHL) as measured by magnetic resonance\n      spectroscopy(MRS) in type 2 diabetic patients with non-alcoholic fatty-liver disease after a\n      26-week treatment of liraglutide, sitagliptin or insulin glargine per day combined with\n      metformin.The primary endpoint will be defined by intrahepatic lipids (IHL) as measured by\n      magnetic resonance spectroscopy (MRS)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recorded Type 2 diabetes diagnosed at least 3 months before the study; At least 3\n             months treatment on a stable dose\uff08\u22671500mg/d\uff09of metformin before the study\n\n          -  7%<HbA1c \u22649%\n\n          -  Clinically diagnosed simple liver steatosis\n\n          -  30-75 years old\n\n          -  Female subjects should be postmenopausal, surgically sterile, or using contraceptives\n             for 3 months before screening and continuing throughout the study;\n\n          -  BMI 20~35 kg/m2 and with a history of stable body weight (\u226410%variation for \u22653\n             months)\n\n          -  intrahepatic lipids (IHL) >10%\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Treatment within the last 3 months with Thiazolidinediones(TZDs), orlistat, insulin,\n             any history of incretin based therapy or any other drugs associated with hepatic\n             steatosis (including but not limited to  glucocorticoids, tamoxifen, amiodarone or\n             methotrexate)\n\n          -  History or current episode of pancreatitis or other disease of the pancrea; Impaired\n             liver function, defined as plasma alanine transaminase(ALT) >2.5 times of upper\n             normal limit\n\n          -  Moderate and severe renal insufficiency defined as MDRD formula glomerular filtration\n             rate<60ml/min/1.73m2\n\n          -  Weekly alcohol intake>14 units for women or >21 units for men\n\n          -  Any history of liver disease including metabolic or auto-immune liver diseases or\n             viral hepatitis\n\n          -  History or family history of medullary thyroid cancer(MTC), or multiple endocrine\n             neoplasia type 2(MEN-2)\n\n          -  Congestive heart failure(NYHA III~IV)\n\n          -  Severe gastric-intestinal diseases\n\n          -  Pregnancy and/or intention of becoming pregnant\n\n          -  Known proliferative retinopathy or maculopathy requiring acute treatment as judged by\n             the Investigator; Use of non-herbal Chinese medicine or other non-herbal local\n             medicine with unknown/unspecified content. Herbal traditional Chinese medicine or\n             other local herbal medicines may, at the Investigator's discretion, be continued\n             throughout the trial at an unchanged dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147925", 
            "org_study_id": "IIS201404"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide", 
                "description": "Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week", 
                "intervention_name": "Liraglutide combined with metformin", 
                "intervention_type": "Drug", 
                "other_name": "Victoza\u00ae, Novo Nordisk"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "description": "The initial dose will be 0.2 unit/kg/d", 
                "intervention_name": "Insulin glargine  combined with metformin", 
                "intervention_type": "Drug", 
                "other_name": "Lantus\u00ae, Sanofi"
            }, 
            {
                "arm_group_label": "Sitagliptin", 
                "description": "The dose throughout the study will be 100mg per day.", 
                "intervention_name": "Sitagliptin combined with metformin", 
                "intervention_type": "Drug", 
                "other_name": "Januvia\u00ae, Merck & Co. Inc."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Sitagliptin", 
                "Insulin", 
                "Metformin", 
                "Insulin, Long-Acting", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-alcoholic fatty liver disease", 
            "Glucagon-like peptide-1 receptor agonists", 
            "Diabetes mellitus, type 2"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "number_of_arms": "3", 
        "official_title": "Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease", 
        "overall_official": {
            "affiliation": "Third Affiliated Hospital, Sun Yat-Sen University", 
            "last_name": "Jianping Weng, Doctor", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the change of intrahepatic lipids (IHL) in type 2 diabetic patients with non-alcoholic fatty-liver disease after a 26-week treatment of liraglutide, sitagliptin or insulin glargine per day combined with metformin.", 
            "measure": "Intrahepatic lipids (IHL)", 
            "safety_issue": "Yes", 
            "time_frame": "26-week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147925"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Jianping Weng", 
            "investigator_title": "professor, vice president, the third affiliated hospital of Sun Yat-sen University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of abdominal subcutaneous adipose tissue(SAT)", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change of visceral adipose tissue(VAT)", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change in hemoglobin A1c(HbA1c)", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}